Juan García‐Revilla

Galectin-3 drives tau-associated neuroinflammation, white matter degeneration and proteomic dysregulation

This study shows that Galectin-3 promotes tau pathology, neuroinflammation, white matter degeneration, and proteomic dysregulation, and that its deletion reduces these effects.

Galectin-3 drives neuroinflammatory amyloid remodeling by stabilizing intermediate Aβ species and altering lysosomal processing

This paper identifies Galectin-3 as a key regulator of amyloid-beta aggregation and microglial dysfunction in Alzheimer's disease, showing its role in neurotoxicity and potential as a therapeutic target.

Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth

This study shows that Galectin-3 depletion reduces immunosuppressive microglia and limits cancer cell growth in brain tumours.

INFLAMMATORY BOWEL DISEASE INDUCES α-SYNUCLEIN AGGREGATION IN GUT AND BRAIN

This study shows that inflammatory bowel disease (IBD) leads to α-synuclein aggregation in the gut and brain, supporting Braak's hypothesis of Parkinson's disease origin in the enteric nervous system.

TET2 regulates the neuroinflammatory response in microglia

This study shows TET2 regulates microglial inflammatory responses through NF-κB-dependent pathways and metabolic changes, suggesting it as a target for neurodegenerative diseases.

Galectin-3, A Novel Endogenous Trem2 Ligand, Regulates Inflammatory Response and Aβ Fibrilation in Alzheimer’s Disease

This study identifies galectin-3 as a novel endogenous TREM2 ligand that regulates microglial activation and Aβ fibrillation in Alzheimer’s disease.